Clinical Trial

A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A19 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-23; most recent amendment 2026-01-06.
Status change: Not Yet Recruiting → Recruiting 2026-01-06
Trial Details
NCT Number NCT06990464
Lead Sponsor Shanghai Institute Of Biological Products
Conditions Advanced Solid Tumors
Enrollment 156 participants
Start Date 2025-06-11
Primary Completion 2028-12-15 (estimated)
Study Completion 2028-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-08